Methods and compositions for treating oxalate-related conditions
The subject invention relates in one aspect to an oxalate degrading composition, which includes at least one oxalate degrading enzyme. The composition includes an enriched insoluble component of fungal bio sample, and the composition is effective to degrade oxalate at a pH of 1.9 or higher. The composition is protected from protease degradation such as pepsin, trypsin and chymotrypsin. The composition is capable of withstanding the conditions of the stomach, small intestines, and/or large intestines of a subject.
1. An oxalate degrading composition, said composition comprising:
at least one first oxalate degrading enzyme obtained from a fungal source, formulated with a stabilizing polymer, wherein the at least one first oxalate degrading enzyme comprises an oxalate decarboxylase enzyme having at least 5% of its maximum activity to degrade oxalate at a pH of 1.9 and at least 5% of its maximum activity to degrade oxalate at a pH of 6.3; the polymer is one or more polymers selected from the group consisting of aminoalkyl methacrylate copolymer, methacrylic acid copolymer, methacrylic ester copolymer and ammonioalkyl methacrylate copolymer; and wherein said fungal source is selected from the group consisting of Agrocybe aegerita, Boletus Flaviporus, Hypsizygus ulmarius and Coprinus comatus.
2. The composition of claim 1 , wherein said composition further comprises a second enzyme comprising an oxalate oxidase that is active at a pH of 5.0-8.0.
3. A method for reducing the amount of oxalate in a subject, comprising:
orally administering a therapeutically effective amount of the composition of claim 1 , wherein said enzyme composition degrades soluble oxalate in the digestive tract of said subject, thereby reducing the amount of oxalate in the subject.
4. The method of claim 3 , wherein said composition further comprises an oxalate oxidase enzyme isolated from a fungal or a plant source that is active at a pH of 5.0-8.0.
5. The method of claim 3 , wherein said oxalate decarboxylase enzyme is isolated from said fungal source grown under fermentation conditions.
6. A method for treating an oxalate-related medical condition in a subject wherein said method comprises orally administering a therapeutically effective amount of the composition of claim 1 to the subject in need, wherein said oxalate-related medical condition is selected from the group consisting of primary hyperoxaluria, autism, secondary hyperoxaluria, Crohn's Disease, inflammatory bowel disease, colitis, cardiac conductance disorder, urolithiasis, vulvodynia, bariatric surgery and oxalosis associated with end-stage renal disease and related enteric disease states.
7. The method of claim 6 , wherein said composition further comprises an oxalate oxidase enzyme that is active at a pH of 5.5-8.0.
8. The method of any one of claims 3 or 6 , wherein said oxalate decarboxylase enzyme degrades soluble oxalate in the stomach of said subject.